Best Grants for Cancer Nonprofits in Virgin Islands

The Clinician Scientist Development Grant (CSDG) by the American Cancer Society supports full-time faculty aiming to become independent clinician scientists while maintaining clinical practice. Eligible applicants must hold a doctoral degree, an active clinical license, and have clinical care experience. The grant provides funding of $135,000 annually for 3 to 5 years, including allowable indirect costs, to advance cancer research in key priority areas.

The American Cancer Society (ACS) and the American Society for Radiation Oncology (ASTRO) co-fund the Clinician Scientist Development Grant (CSDG), aimed at advancing the research careers of clinician scientists in radiation oncology. Eligible applicants are full-time faculty members at U.S. institutions with a doctoral degree and an active clinical license. The grant supports research for 3 to 5 years, providing $135,000 annually for direct costs, plus allowable indirect costs, while encouraging diversity in applications.

The Institutional Research Grants (IRG) program by the American Cancer Society provides essential seed funding for newly independent investigators to launch cancer research projects. Aimed at junior faculty, these grants offer $120,000 annually for three years, supporting the development of preliminary results necessary for competing for larger national grants. Eligible applicants must be at US academic institutions and hold the rank of Associate or Full Professor, with a proven track record in research and mentorship.

The Cancer Research Education Grants Program (R25) aims to enhance research education in areas crucial to the NIH mission. This program supports innovative courses that develop skills in cancer research, covering topics such as prevention, diagnosis, and treatment. Grant applications are encouraged to be creative and state-of-the-art, addressing the needs of patients and their families. Key deadlines for applications span from January 2024 to September 2026, ensuring ongoing support for educational initiatives.

Bristol Myers Squibb Foundation Inc supports independent medical education to enhance healthcare professional competence and improve patient health outcomes. Their mission is to be a global leader in innovative medical education, focusing on evidence-based activities that address critical gaps in knowledge. By fostering excellence in healthcare, they aim to ensure measurable improvements in performance and patient outcomes across various disease areas.

Mesothelioma Applied Research Foundation Inc

The Mesothelioma Applied Research Foundation is the only nonprofit charity organization dedicated to ending mesothelioma, and the suffering caused by this cancer, by:

• funding research to improve treatment options;
• providing treatment support and education for patients and their families;
• and advocating for federal funding of research.

The mission of the Mesothelioma Applied Research Foundation spans across four distinct areas: through research, education, support, and advocacy the Foundation seeks to eradicate the vicious effects of mesothelioma. Led by the Board of Directors, our team works collaboratively to develop and administer our programs, and to fundraise to pay for those programs (the Foundation is funded by private individual and corporate contributions only — it does not receive any government funding).

Bret A. Rosenthal Patient Assistance Fund

Patients diagnosed with cancer at a younger age often face greater financial burdens. This is a time in a patient’s life when they are raising a family, starting a career, or have not accumulated savings. For patients 49 and under, the Foundation administers the Bret A. Rosenthal Patient Assistance Fund grant program. This program is made possible by the generosity of the Rosenthal family.

Mesothelioma Applied Research Foundation Inc

The Mesothelioma Applied Research Foundation is the only nonprofit charity organization dedicated to ending mesothelioma, and the suffering caused by this cancer, by:

• funding research to improve treatment options;
• providing treatment support and education for patients and their families;
• and advocating for federal funding of research.

The mission of the Mesothelioma Applied Research Foundation spans across four distinct areas: through research, education, support, and advocacy the Foundation seeks to eradicate the vicious effects of mesothelioma. Led by the Board of Directors, our team works collaboratively to develop and administer our programs, and to fundraise to pay for those programs (the Foundation is funded by private individual and corporate contributions only — it does not receive any government funding).

Patient Travel Grant Program

A mesothelioma diagnosis and treatment often require the patient and their family to incur numerous expenses as part of their treatment. Travel to treatment, alone, can cause a significant financial burden on the patient, which might even cause the patient to not seek treatment away from home, even it’s their best option. To ensure that all patients have the ability to seek specialized help and treatments, the Mesothelioma Applied Research Foundation administers its Travel Grant Program.

The Meso Foundation’s Patient Travel Grant Program, founded by Mary and Bob Cosentino, provides travel grants to patients and one caregiver traveling for an initial consult and/or for clinical trial treatments.

• The type of eligible travel must fall into at least one of these two categories:
  • One trip for one initial consultation with a mesothelioma specialist.
  • Multiple trips to participate in an interventional clinical trial (found on clinicaltrials.gov).

Pershing Square Lotus Award for Ovarian Cancer Research

The Pershing Square Foundation (PSF) has worked across sectors to catalyze innovative approaches to the most difficult problems. Talented individuals have always been at the center of our approach. We aim to support leaders who transform systems, embrace new paradigms, and have an innate drive to make an impact.

PSF has funded pioneering cancer researchers through the Pershing Square Sohn Cancer Research Alliance for over a decade and supported women’s health initiatives in New York City. Through this Request for Proposals (RFP), PSF aims to combine these two priority areas of women’s health and cancer to shine a light on one of the most understudied and underfunded cancers—ovarian cancer. Ovarian cancer is the deadliest gynecologic cancer, with 80% of women diagnosed at an advanced stage. Only 27% of women diagnosed during an advanced stage survive for five years. Ovarian cancer remains a disease with a poor prognosis due to limited early detection and treatment options.

PSF supports research efforts by 

• deploying capital quickly, 
• funding high-risk, high-reward ideas, 
• bringing new perspectives into a field, 
• encouraging collaboration, and 
• leveraging our vast network. We challenge our scientific partners to think creatively and across silos, to spur innovation to fight ovarian cancer.

Through the Pershing Square Lotus Award for Ovarian Cancer Research, PSF is looking for investigators who are either already working on a promising project in ovarian cancer or in another type of cancer that could have an impact on ovarian cancer. Grantees each receive $250,000 a year for three years, totaling $750,000.

Researchers who are not studying ovarian cancer are encouraged to apply and required to find a collaborator with experience in ovarian cancer research.

This award aims to 

• inspire investigators with unique expertise to apply their knowledge to ovarian cancer and 
• empower ovarian cancer researchers to pursue their boldest, most innovative ideas. Facing a disease where too few have survived to-date, PSF ultimately aims to create a culture around ovarian cancer that offers women hope, akin to the breast cancer community. PSF is passionate about changing outcomes for tens of thousands of women a year and is hopeful that future scientific discoveries will allow for more survivors who can share their stories for years to come.

The Accelerating Impact for Hard-to-Treat Cancers Award, offered by the Children's Cancer Research Fund, focuses on pre-clinical research to enhance treatment outcomes for pediatric cancers that are difficult to treat. The award supports innovative studies, including pilot projects and the development of new technologies. As a nonprofit, CCRF has invested over $235 million in initiatives since 1981, aiming to improve therapies and support for children battling cancer, thereby fostering safer and more effective treatment options.

The Eliminating Disparities in Childhood Cancers Award, offered by the Children’s Cancer Research Fund, supports innovative research aimed at reducing health disparities in childhood cancer. This initiative prioritizes proposals that identify modifiable risk factors and mechanisms of disparities, emphasizing the importance of improving access to care and treatment outcomes. With over $235 million invested since 1981, CCRF is dedicated to enhancing the quality of life for children and families affected by cancer.

The Healthy After Cancer Award, offered by the Children's Cancer Research Fund, focuses on enhancing the quality of life for childhood cancer survivors. This funding supports research aimed at addressing the long-term effects of cancer therapy, prioritizing survivorship interventions over new treatment development. With a commitment to improving health outcomes for young survivors, this award underscores the importance of addressing unique challenges faced by this population.

About Us

Children’s Cancer Research Fund is a national nonprofit dedicated to ending childhood cancer. Our main focus is to support the research of bright scientists across the country whose ideas can make the greatest impact for children fighting cancer. We also fund resources and programs that help kids and families as they navigate the difficult experience of cancer treatment and survivorship.

Since 1981, we’ve contributed over $235 million to research, support programs for children and families, and awareness and education outreach. In 2024, over 81 percent of funds raised went directly to these program services areas.

Children’s Cancer Research Fund (CCRF) is a national nonprofit committed to finding safer, more effective therapies for kids battling cancer. Thanks to donors and partners around the country, we have contributed over $235 million to research, education and awareness, and quality-of-life programs for childhood cancer families. We believe kids deserve safer, less toxic treatments, and we’re committed to funding groundbreaking research and services that enhance healing and care.

In 2026, Children’s Cancer Research Fund will focus our research funding efforts on three main areas:

• Hard-to-Treat Cancers
• Survivorship
• Health Disparities

Accelerating Hope: Clinical Trials for Hard-to-Treat Cancers Award

This funding opportunity is limited to support for clinical trials focused on hard-to-treat cancers, prioritizing Phase 0 – Phase 2 studies. Learn more about eligibility criteria and other key details below.

The American Heart Association is seeking proposals to study the prevalence and treatment of cardiovascular, kidney, and metabolic diseases among cancer patients and survivors. Given the over 16.7 million cancer survivors in the U.S., this research aims to highlight critical health disparities, identify treatment modalities, and explore shared risk factors. Applications focusing on underrepresented populations and utilizing real-world data sources are especially encouraged, aiming to improve health outcomes in this vulnerable group.

The ASCO Clinical Oncology & Research Experience (ASCO CORE) offers medical students immersive exposure to the field of oncology through shadowing experiences in clinical and research settings. With two distinct tracks, participants can gain insights into patient care or research practices, guided by mentors. Eligible students must be enrolled in a U.S. DO or MD program and maintain a good academic record. This program aims to inspire the next generation of oncology professionals.

This funding opportunity aims to enhance cancer research among American Indian and Alaska Native populations, focusing on prevention, diagnosis, and treatment in rural areas. The initiative seeks to reduce cancer incidence and mortality rates while ensuring that research findings significantly improve health outcomes for these communities. Eligible organizations are invited to apply, with applications undergoing rigorous peer review to ensure only the most promising projects receive funding.

The AACR-Torrey Coast Foundation Transpacific Gastric and Esophageal Cancer Research Partnership Grant supports innovative research on upper gastrointestinal malignancies, which are responsible for over one million deaths globally in 2023. This grant encourages collaboration between U.S. and Asian institutions, focusing on resistance, metastasis, and novel treatment strategies. Proposals should detail plans for clinical translation and are open to researchers at all career stages, especially those new to upper GI cancer research.

The Joyce Bytof Memorial Cancer Survivors Scholarship, established by Joyce Bytof in collaboration with the American Cancer Society, supports childhood cancer survivors graduating from specific Wisconsin high schools. This scholarship aims to assist them in pursuing higher education despite the financial and academic challenges posed by their experiences. Joyce's legacy continues to inspire hope and resilience among young survivors as they strive for academic success and a brighter future.

Pfizer is offering a grant opportunity for independent medical education initiatives focused on Muscle Invasive Bladder Cancer (MIBC). This program aims to address the current knowledge gaps among healthcare professionals regarding emerging treatment data and its potential impact on clinical practices. By collaborating with Astellas, Pfizer seeks proposals that enhance awareness and understanding of the evolving MIBC landscape, ultimately improving patient outcomes in this critical area of unmet medical need.

The Radiation Oncology Institute (ROI) Innovation Awards, offered by the American Society for Radiation Oncology, aim to accelerate innovative ideas in radiation therapy. Currently accepting applications for the 2026 awards, the program focuses on optimizing the combination of radiation therapy and immunotherapy to enhance cancer treatment outcomes. By supporting practical research, ROI strives to transform clinical practices and improve patient care in the fight against cancer.

The 2026 Radiation Oncology Institute- Innovation Awards aim to advance cancer treatment by integrating radiation therapy with immunotherapy. Researchers are invited to submit proposals that explore optimal combinations of these modalities to enhance patient outcomes. Funding of up to $100,000 over two years will support projects focused on identifying effective treatment strategies, understanding mechanisms of synergy, and improving access to care. This initiative represents a significant opportunity for innovative research in oncology.

Incyte Corporation invites organizations to submit membership requests aimed at enhancing healthcare access for patients and advocates. As a biopharmaceutical leader, Incyte supports initiatives that align with its mission to improve patient lives through grants and contributions. Eligible entities include medical schools, associations, non-profits, and advocacy groups. Requests should comply with Incyte's regulatory standards and be submitted at least 60 days prior to the required decision date.

Incyte Corporation, a biopharmaceutical leader, offers healthcare sponsorships to support organizations focused on improving patient care and access to healthcare information. Eligible applicants include medical schools, associations, non-profits, advocacy groups, and hospitals. Requests should align with Incyte's commitment to enhancing the lives of patients affected by cancer and other diseases, ensuring compliance with regulatory guidelines. Organizations must enter a written agreement with Incyte to receive funding.

The ACS-ASTRO Felix Feng, MD Clinician Scientist Development Award supports practicing radiation oncologists engaged in research that enhances health across the cancer continuum. Funded by the American Cancer Society and ASTRO, this award provides $730,000 over three to five years, aiming to advance the field of radiation oncology and improve patient care through innovative research and collaboration.

The ASTRO-ACS Clinician Scientist Development Award aims to support full-time faculty members in radiation oncology who aspire to become independent investigators. Co-funded by the American Cancer Society and the American Society for Radiation Oncology, this grant provides $135,000 per year for 3 to 5 years, along with 8% allowable indirect costs. It encourages applications from underrepresented groups and those with disabilities, fostering diversity in cancer research.

The Cancer Care Specialists of Illinois Scholarship offers financial assistance for tuition to high school seniors and healthcare professionals in oncology/hematology within Central and Southern Illinois. The scholarship supports educational pursuits and professional development in these fields. Applications are accepted monthly, with a deadline for 2025 set for December 1st. Eligible candidates must maintain a GPA of 3.0 and reside in specific counties, ensuring support for local talent in healthcare.

This funding opportunity from the Patient-Centered Outcomes Research Institute aims to enhance health decision-making through comparative clinical effectiveness research, focusing on critical areas such as cancer, maternal health, and mental health. The initiative encourages robust observational studies that utilize existing data to derive patient-centered insights. Applications must address specific themes approved by PCORI and demonstrate potential benefits to the U.S. healthcare system, thus ensuring relevance and stakeholder engagement in research efforts.

The Patient-Centered Outcomes Research Institute (PCORI) is announcing funding for comparative clinical effectiveness research across the cancer care continuum. This initiative aims to empower researcher-community partnerships to tackle significant healthcare challenges faced by patients and caregivers in the U.S. The focus is on enhancing care delivery and outcomes by addressing barriers to screening, treatment, and follow-up care for cancer patients. Applications are encouraged to identify strategies that improve patient-centered outcomes.